{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:05:17Z","timestamp":1790791517844,"version":"4.1.0"},"reference-count":42,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T00:00:00Z","timestamp":1608854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002738","name":"Assistance Publique - H\u00f4pitaux de Paris","doi-asserted-by":"publisher","award":["F101H1"],"award-info":[{"award-number":["F101H1"]}],"id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Epithelial ovarian cancers (EOC) are usually diagnosed at an advanced stage and managed by complete macroscopic cytoreductive surgery (CRS) and systemic chemotherapy. Peritoneal recurrence occurs in 60% of patients and may be due to microscopic peritoneal metastases (mPM) which are neither eradicated by surgery nor controlled by systemic chemotherapy. The aim of this study was to assess and quantify the prevalence of residual mPM after complete macroscopic CRS in patients with advanced high-grade serous ovarian cancer (HGSOC). Methods: A prospective study conducted between 1 June 2018 and 10 July 2019 in a single referent center accredited by the European Society of Gynecological Oncology for advanced EOC management. Consecutive patients presenting with advanced HGSOC and eligible for complete macroscopic CRS were included. Up to 13 peritoneal biopsies were taken from macroscopically healthy peritoneum at the end of CRS and examined for the presence of mPM. A mathematical model was designed to determine the probability of presenting at least one mPM after CRS. Results: 26 patients were included and 26.9% presented mPM. There were no differences in characteristics between patients with or without identified mPM. After mathematical analysis, the probability that mPM remained after complete macroscopic CRS in patients with EOC was 98.14%. Conclusion: Microscopic PM is systematically present after complete macroscopic CRS for EOC and could be a relevant therapeutic target. Adjuvant locoregional strategies to conventional surgery may improve survival by achieving microscopic CRS.<\/jats:p>","DOI":"10.3390\/jcm10010041","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T09:30:19Z","timestamp":1608888619000},"page":"41","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Microscopic Peritoneal Residual Disease after Complete Macroscopic Cytoreductive Surgery for Advanced High Grade Serous Ovarian Cancer"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6855-9754","authenticated-orcid":false,"given":"Henri","family":"Aza\u00efs","sequence":"first","affiliation":[{"name":"Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, 75013 Paris, France"},{"name":"U1189-ONCO-THAI-Laser Assisted Therapy and Immunotherapies for On-cology, CHU Lille, Universit\u00e9 de Lille, INSERM, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0979-3310","authenticated-orcid":false,"given":"Anne-Sophie","family":"Vignion-Dewalle","sequence":"additional","affiliation":[{"name":"U1189-ONCO-THAI-Laser Assisted Therapy and Immunotherapies for On-cology, CHU Lille, Universit\u00e9 de Lille, INSERM, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Carrier","sequence":"additional","affiliation":[{"name":"Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, 75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Augustin","sequence":"additional","affiliation":[{"name":"AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Pathology, 75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Da Ma\u00efa","sequence":"additional","affiliation":[{"name":"AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Pathology, 75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Penel","sequence":"additional","affiliation":[{"name":"AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Centre de Pharmaco-\u00e9pid\u00e9miologie de l\u2019APHP (CEPHEPI), 75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Belghiti","sequence":"additional","affiliation":[{"name":"Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, 75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Nikpayam","sequence":"additional","affiliation":[{"name":"Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, 75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Gonthier","sequence":"additional","affiliation":[{"name":"Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, 75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurine","family":"Ziane","sequence":"additional","affiliation":[{"name":"U1189-ONCO-THAI-Laser Assisted Therapy and Immunotherapies for On-cology, CHU Lille, Universit\u00e9 de Lille, INSERM, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1208-7153","authenticated-orcid":false,"given":"Serge","family":"Mordon","sequence":"additional","affiliation":[{"name":"U1189-ONCO-THAI-Laser Assisted Therapy and Immunotherapies for On-cology, CHU Lille, Universit\u00e9 de Lille, INSERM, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Collinet","sequence":"additional","affiliation":[{"name":"U1189-ONCO-THAI-Laser Assisted Therapy and Immunotherapies for On-cology, CHU Lille, Universit\u00e9 de Lille, INSERM, F-59000 Lille, France"},{"name":"CHRU Lille, Jeanne de Flandre Hospital, Department of Gynecology, 59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffroy","family":"Canlorbe","sequence":"additional","affiliation":[{"name":"Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, 75013 Paris, France"},{"name":"Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine (CRSA), Sorbonne University, INSERM UMR_S_938, 75020 Paris, France"},{"name":"Institut Universitaire de Canc\u00e9rologie (IUC), Sorbonne University, 75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Uzan","sequence":"additional","affiliation":[{"name":"Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, 75013 Paris, France"},{"name":"Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine (CRSA), Sorbonne University, INSERM UMR_S_938, 75020 Paris, France"},{"name":"Institut Universitaire de Canc\u00e9rologie (IUC), Sorbonne University, 75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/annonc\/mdu116","article-title":"Optimal treatment of early-stage ovarian cancer","volume":"25","author":"Collinson","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2006.07.004","article-title":"\u201cOptimal\u201d cytoreduction for advanced epithelial ovarian cancer: A commentary","volume":"103","author":"Eisenkop","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0959-8049(11)70152-6","article-title":"Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer","volume":"47","author":"Vergote","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2012.02.024","article-title":"Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: Redefining \u2018optimal\u2019 residual disease","volume":"125","author":"Chang","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1245\/s10434-012-2446-8","article-title":"Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer","volume":"19","author":"Chang","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1040-1741(09)79358-3","article-title":"Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO)","volume":"2009","author":"Thigpen","year":"2009","journal-title":"Yearb. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Soslow","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Elattar, A., Bryant, A., Winter-Roach, B.A., Hatem, M., and Naik, R. (2011). Optimal primary surgical treatment for advanced epithelial ovarian cance. Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd.. Available online: http:\/\/onlinelibrary.wiley.com.doc-distant.univ-lille2.fr\/doi\/10.1002\/14651858.CD007565.pub2\/abstract.","DOI":"10.1002\/14651858.CD007565.pub2"},{"key":"ref_12","first-page":"CD008765","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","volume":"2","author":"Lopes","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4251\/wjgo.v2.i2.102","article-title":"Peritoneal carcinosis of ovarian origin","volume":"2","author":"Fagotti","year":"2010","journal-title":"WorldJ. Gastrointest. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.suronc.2017.01.001","article-title":"Dealing with microscopic peritoneal metastases of epithelial ovarian cancer. A surgical challenge","volume":"26","author":"Estevez","year":"2017","journal-title":"Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/GCO.0b013e32831f8f32","article-title":"Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer","volume":"21","author":"Sugarbaker","year":"2009","journal-title":"Curr. Opin. Obs. Gynecol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"642.e1","DOI":"10.1016\/j.ajog.2008.06.052","article-title":"Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma","volume":"199","author":"Fagotti","year":"2008","journal-title":"Am. J. Obs. Gynecol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jogoh.2019.03.017","article-title":"Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Long text of the Joint French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Part 1: Diagnostic exploration and staging, surgery, perioperative care, and pathology","volume":"48","author":"Huchon","year":"2019","journal-title":"J. Gynecol. Obs. Hum. Reprod."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1808424","article-title":"A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms","volume":"380","author":"Harter","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"FIGO Committee on Gynecologic Oncology Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynecol. Obs."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00276-008-0456-9","article-title":"Peritoneal surface area: Measurements of 40 structures covered by peritoneum: Correlation between total peritoneal surface area and the surface calculated by formulas","volume":"31","author":"Albanese","year":"2009","journal-title":"Surg. Radiol. Anat."},{"key":"ref_21","first-page":"1208","article-title":"The Utility of Peritoneal Biopsy and Omentectomy in the Upstaging of Apparent Early Ovarian Cancer","volume":"21","author":"Shroff","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"81.e1","DOI":"10.1016\/j.ajog.2006.08.043","article-title":"Occult metastasis in early ovarian cancers: Risk factors and associated prognosis","volume":"196","author":"Ayhan","year":"2007","journal-title":"Am. J. Obs. Gynecol."},{"key":"ref_23","first-page":"949","article-title":"Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma","volume":"80","author":"Soper","year":"1992","journal-title":"Obs. Gynecol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1001\/jama.1983.03340220040030","article-title":"Staging laparotomy in early ovarian cancer","volume":"250","author":"Young","year":"1983","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.1525-1438.1998.09783.x","article-title":"The yield of surgical staging in presumed early stage ovarian cancer: Benefits or doubts?","volume":"8","author":"Schueler","year":"1998","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_26","first-page":"213","article-title":"Analysis of failures and clinical outcome of advanced epithelial ovarian cancer in patients with microscopic residual disease at second-look reassessment following primary cytoreductive surgery and first-line platinum-based chemotherapy","volume":"34","author":"Gadducci","year":"2013","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/IGC.0000000000000007","article-title":"Ovarian Cancer: Sites of Recurrence","volume":"23","author":"Amate","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.pdpdt.2015.07.006","article-title":"Targeted approaches and innovative illumination solutions: A new era for photodynamic therapy applications in gynecologic oncology?","volume":"13","author":"Betrouni","year":"2016","journal-title":"Photodiagnosis Photodyn."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nm.2472","article-title":"Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-\u03b1 targeting: First in-human results","volume":"17","author":"Themelis","year":"2011","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"32144","DOI":"10.18632\/oncotarget.8282","article-title":"Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17","volume":"7","author":"Tummers","year":"2016","journal-title":"Oncotarget"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1158\/1078-0432.CCR-15-2640","article-title":"A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer","volume":"22","author":"Hoogstins","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1245\/s10434-014-3901-5","article-title":"Cytoreductive Surgery Under Aminolevulinic Acid-Mediated Photodynamic Diagnosis Plus Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Carcinomatosis from Ovarian Cancer and Primary Peritoneal Carcinoma: Results of a Phase I Trial","volume":"21","author":"Liu","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","article-title":"Pharmacokinetic Problems in Peritoneal Drug Administration: Tissue Penetration and Surface Exposure","volume":"89","author":"Dedrick","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-006-9182-x","article-title":"A Systematic Review on the Efficacy of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei","volume":"14","author":"Yan","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jogoh.2019.03.018","article-title":"Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: Systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up)","volume":"48","author":"Huchon","year":"2019","journal-title":"J. Gynecol. Obs. Hum. Reprod."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1200\/EDBK_158927","article-title":"Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer","volume":"35","author":"Gourley","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Baydoun, M., Moral\u00e8s, O., Frochot, C., Ludovic, C., Leroux, B., Thecua, E., Ziane, L., Grabarz, A., Kumar, A., and De Schutter, C. (2020). Photodynamic Therapy Using a New Folate Receptor-Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles with Immunoactivating Properties. J. Clin. Med., 9.","DOI":"10.3390\/jcm9041185"},{"key":"ref_40","unstructured":"Aza\u00efs, H., Collinet, P., Delhem-Fellahi, N., Morales, O., Mordon, S., Frochot, C., Vanderesse, R., and Stallivieri, A. (2019). Pyropheophorbide Conjugate and Use Thereof in the Treatment of Cancer and As a Fluorescent Marker. (WO2019016397 (A1)), WIPO Patent."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.3802\/jgo.2020.31.e34","article-title":"Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III\/IV ovarian, tubal, and primary peritoneal cancer","volume":"31","author":"Tate","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/1\/41\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:46:02Z","timestamp":1760179562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/1\/41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,25]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["jcm10010041"],"URL":"https:\/\/doi.org\/10.3390\/jcm10010041","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,25]]}}}